Tim Lu is the chief medical officer of DICE Therapeutics. Prior to DICE, Tim was a senior medical director at Genentech in the OMNI early clinical development group. At Genentech, Tim served as the disease area expert in inflammatory bowel diseases where we he led efforts in the development of therapeutics in inflammatory bowel disease (IBD), including the Phase 2 studies of an anti-integrin, etrolizumab, and an IL-22Fc fusion protein in ulcerative colitis. He also led the Phase 2 program of the company’s BTK inhibitor, fenebrutinib, in chronic spontaneous urticaria. In addition to these clinical programs, Tim also co-led efforts to understand the potential role of the microbiome in IBD as well as the utility of magnetic resonance enterography as a tool for clinical development in Crohn’s disease. Prior to Genentech, Tim was at the University of California, San Francisco, where he was an internal medicine resident, gastroenterology fellow, postdoctoral fellow and assistant adjunct professor.
Tim holds M.D. and Ph.D. degrees from the University of Texas Southwestern Medical Center and B.S. in biology from Yale University.